Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors

@article{Sansone2019SpecificAN,
  title={Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors},
  author={A. Sansone and R. Lauretta and S. Vottari and A. Chiefari and A. Barnabei and F. Romanelli and M. Appetecchia},
  journal={Cancers},
  year={2019},
  volume={11}
}
The diagnosis of neuroendocrine tumors (NETs) is a challenging task: Symptoms are rarely specific, and clinical manifestations are often evident only when metastases are already present. However, several bioactive substances secreted by NETs can be included for diagnostic, prognostic, and predictive purposes. Expression of these substances differs between different NETs according to the tumor hormone production. Gastroenteropancreatic (GEP) NETs originate from the diffuse neuroendocrine system… Expand
Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
TLDR
There is a strong need for new biomarkers and follow-up modalities aimed to improve the outcome of PanNEN patients, and this review provides the most updated panorama on PanNen biomarkers. Expand
Update on Histological Reporting Changes in Neuroendocrine Neoplasms
TLDR
The heterogeneity of NEN regarding the organ of origin, differentiation and molecular subtypes make development of personalised therapy a challenge needing more international and interdisciplinary collaborations and clinical trials allowing stratification according to biological subgroups. Expand
Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance
TLDR
This study provides, for the first time, a comprehensive metabolic profile of NET patients and identifies a distinctive metabolic signature in plasma of potential clinical use, selecting a reduced set of metabolites of high diagnostic accuracy. Expand
Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma
TLDR
It is concluded that plasma CGA can serve as an appropriate complement to metanephrines assays in laboratory diagnosis of PPGL patients and under clinical conditions increasing adrenergic activity. Expand
Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors
TLDR
Two novel nomogram models based on sex, age and serum NSE levels to preoperatively predict the histologic grades in GEP-NETs to assist the clinical decision-making are proposed and demonstrated the clinical usefulness of both models. Expand
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
TLDR
NET mRNA blood levels provide early objective genomic identification of residual disease and may facilitate management and help to predict recurrence after surgery. Expand
A Challenging Case of Carcinoid Crisis in a Patient With Neuroendocrine Tumor
TLDR
A quick response to the somatostatin analog therapy, octreotide, was helpful to confirm the diagnosis of carcinoid crisis, which is a rare cause of shock and difficult to identify in the presence of infection. Expand
New Biomarkers in Cancers
TLDR
The latest insights on biomarkers in cancers are presented in 33 up-to-the-minute research papers and reviews summing up the tremendous progress in this interesting and important field of research. Expand
Utilità e limiti dei biomarcatori nella diagnosi e nella gestione clinica dei NET
TLDR
Tallahi marcatori si distinguono fra aspecifici, comuni a più neoplasie, e specifici per alcuni tumori per al cuno tumori. Expand
Nitrosonaphthol reaction-assisted SERS assay for selective determination of 5-hydroxyindole-3-acetic acid in human urine.
TLDR
It is concluded that the present SERS-based method can provide a valuable alternative to conventional colorimetric assay for clinical diagnosis, evaluating prognosis, and monitoring of treatment in carcinoid tumors. Expand
...
1
2
...

References

SHOWING 1-10 OF 89 REFERENCES
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
TLDR
Clinicians aware of the physiologic role of chromogranin A and its secretion in a variety of non-NET-related pathologic conditions can use this protein as a moderately effective tumor biomarker in the management of GEP-NETs. Expand
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
TLDR
Biochemical markers are applied in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) for diagnostic, prognostic or predictive purposes and the relevant hormone serves as a diagnostic and prognostic marker. Expand
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
TLDR
This review provides an update on the use of somatostatin analogues in the management of GEP NETs and discusses novel clinical strategies based on SSTR 2 gene transfer therapy. Expand
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
TLDR
The role of miRNAs in GEP-NET carcinogenesis and their possible use as novel diagnostic, prognostic and predictive biomarkers are summarized. Expand
Role of biomarker tests for diagnosis of neuroendocrine tumours
TLDR
The diagnosis of gastroenteropancreatic neuroendocrine tumours (NETs) should be made by histological evaluation of tumour tissue, as the diagnostic accuracy of current circulating and imaging biomarkers is insufficient. Expand
Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrineExpand
Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
TLDR
The role of systemic therapy in treating NETs of gastroenteropancreatic origin is explained, identifying benefits and limitations and the rationale for some of the newer systemic targeted therapies that are showing promise in the clinic is discussed. Expand
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
TLDR
The utility of CgA measurement in NETs is reviewed and its biological role and the clinical value of its measurement are described, showing some utility in predicting disease recurrence, outcome, and efficacy of therapy. Expand
A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors
TLDR
A potential biomarker for GEP-NETs included MiR-21 (small bowel and pancreas), but this epithelial tumor marker requires prospective validation and significant scientific investigation remains to identify and demonstrate neuroendocrine specificity and to validate candidate miRNA biomarkers. Expand
Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
TLDR
This review provides a view of the changing methodology of biomarker development and the application of biomathematical analyses to redefining detection and treatment and presents a description and consensus on current advances in transcript analysis, miRNA measurement and circulating tumor cell identification. Expand
...
1
2
3
4
5
...